**Bertilsson 1995** Bertilsson, L. (1995). Geographical / Interracial Differences/interracial differences in Current State of Knowledge of Cytochromes P450 ( CYP ). *Clin Pharmacokinet Concepts*. 1995;polymorphic drug oxidation. Clinical pharmacokinetics, 29(3):), 192-209. 

**Cho 2002** Cho JY, Yu KS, Jang IJ, Yang BH, Shin SG, Yim DS. Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic em genotype for CYP2C19. *Br J Clin Pharmacol*. 2002;53(4):393-397.

**Desta 2002** Desta, Z,., Zhao, X,., Shin, J,. G., & Flockhart DA., D. A. (2002). Clinical Significancesignificance of the Cytochromecytochrome P450 2C19 Genetic Polymorphism. *Clin*genetic polymorphism. Clinical pharmacokinetics,  *Pharmacokinet*. 2002;41(12):), 913-958.

**FDA** U.S. Food and Drug Administration. Drug development and drug interactions: table of substrates, inhibitors and inducers. <Website fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.html (2017). Accessed 04 March 2019.

**Goldstein 2001** Goldstein JA., J. A. (2001). Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. *Br J Clin Pharmacol*. 2001;British journal of clinical pharmacology, 52(4):), 349-355.

**Guest 2011** Guest EJ, Aarons L, Houston JB, Rostami-Hodjegan A, Galetin A. Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions. Drug Metab Dispos. 2011 Feb;39(2):170-3.

**Iga 2016** Iga K. Dynamic and Static Simulations of Fluvoxamine-Perpetrated Drug-Drug Interactions Using Multiple Cytochrome P450 Inhibition Modeling, and Determination of Perpetrator-Specific CYP Isoform Inhibition Constants and Fractional CYP Isoform Contributions to Vic. *J Pharm Sci*.Victim Clearance. Journal of Pharmaceutical Sciences. 2016 Mar;105(3):1307-1317–17.

**Liu 2005** Liu KH, Kim MJ, Shon JH, et al. Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro. *Xenobiotica*. 2005;35(1):27-38

**Wu 2014** Wu F, Gaohua L, Zhao P, Jamei M, Huang S-M, Bashaw ED, et al. Predicting Nonlinear Pharmacokinetics of Omeprazole Enantiomers and Racemic Drug Using Physiologically Based Pharmacokinetic Modeling and Simulation: Application to Predict Drug/Genetic Interactions. *Pharmaceutical Research*. 2014 Aug;31(8):1919–29.

**Yao 2003**  Yao C, Kunze KL, Trager WF, Kharasch ED, Levy RH. Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19. *Drug Metab Dispos*. 2003;31(5):565-571.

**Yasui-Furukori 2004** Yasui-Furukori N, Takahata T, Nakagami T, et al. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. *Br J Clin Pharmacol*. 2004;57(4):487-494.

**Yu 2001** Yu K, Yim DS, Cho J-Y, Park SS. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clinical Pharmacology & Therapeutics. 2001 Apr;69(4):266–73.